JAJean-Luc Ardilouze

Jean-Luc Ardilouze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Luc Ardilouze has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Julie Ménard

    Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

    6 shared publications
  • Jean-Patrice Baillargeon

    Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada; Endocrine Division, Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada

    5 shared publications
  • Marie-France Hivert

    Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Population Medicine, Harvard Pilgrim Health Care Institute, Landmark Center, Boston, Massachusetts, United States; Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, United States

    3 shared publications
  • Maude Gagnon-Auger

    Endocrinology Division, University of Sherbrooke, Sherbrooke, Quebec

    3 shared publications
  • Pascal Brassard

    Department of Medicine, Division of Endocrinology, University Hospital Center of Sherbrooke, University of Sherbrooke, Sherbrooke, Quebec, Canada; and Clinical Research Center, University Hospital Center of Sherbrooke, Sherbrooke, Quebec, Canada

    3 shared publications
  • Annie Ouellet

    Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Obstetrics and Gynecology, Université de Sherbrooke, Sherbrooke, Quebec, Canada

    2 shared publications

Latest Publications

  • Can a Mixture of Insulin and a Nonsteroidal Anti-inflammatory Drug Prolong Insulin Pump Catheter Wear Time in Adults With Type 1 Diabetes?

    by Jean-Luc Ardilouze, Fernand Gobeil, Ran Cheng, Julie Ménard, Danijela Bovan, Virginie Messier, Martin Savard, Jean-Patrice Baillargeon, Rémi Rabasa-Lhoret

  • Self-Monitoring of Blood Glucose: A Complementary Method Beyond the Oral Glucose Tolerance Test to Identify Hyperglycemia During Pregnancy

    by Amélie Ardilouze, Patricia Bouchard, Marie-France Hivert, Catherine Simard, Catherine Allard, Marie-Pierre Garant, Julie Ménard, Annie Ouellet, Ghislaine Houde, Marie-Hélène Pesant, et al.


  • Open Access

    Higher maternal leptin levels at second trimester are associated with subsequent greater gestational weight gain in late pregnancy

    by Marilyn Lacroix, Marie-Claude Battista, Myriam Doyon, Julie Moreau, Julie Patenaude, Laetitia Guillemette, Julie Ménard, Jean-Luc Ardilouze, Patrice Perron, Marie-France Hivert

    Excessive gestational weight gain (GWG) is associated with adverse pregnancy outcomes. In non-pregnant populations, low leptin levels stimulate positive energy balance. In pregnancy, both the placenta and adipose tissue contribute to circulating leptin levels. We tested whether maternal leptin levels are associated with subsequent GWG and whether this association varies depending on stage of pregnancy and on maternal body mass index (BMI). This prospective cohort study included 675 pregnant women followed from 1st trimester until delivery. We collected anthropometric measurements, blood samples at 1st and 2nd trimester, and clinical data until delivery. Maternal leptin was measured by ELISA (Luminex technology). We classified women by BMI measured at 1st trimester: BMI < 25 kg/m2 = normal weight; 25 ≤ BMI < 30 kg/m2 = overweight; and BMI ≥ 30 kg/m2 = obese. Women gained a mean of 6.7 ± 3.0 kg between 1st and 2nd trimester (mid pregnancy GWG) and 5.6 ± 2.5 kg between 2nd and the end of 3rd trimester (late pregnancy GWG). Higher 1st trimester leptin levels were associated with lower mid pregnancy GWG, but the association was no longer significant after adjusting for % body fat (%BF; β = 0.38 kg per log-leptin; SE = 0.52; P = 0.46). Higher 2nd trimester leptin levels were associated with greater late pregnancy GWG and this association remained significant after adjustment for BMI (β = 2.35; SE = 0.41; P < 0.0001) or %BF (β = 2.01; SE = 0.42; P < 0.0001). In BMI stratified analyses, higher 2nd trimester leptin levels were associated with greater late pregnancy GWG in normal weight women (β = 1.33; SE = 0.42; P = 0.002), and this association was stronger in overweight women (β = 2.85; SE = 0.94; P = 0.003 – P for interaction = 0.05). Our results suggest that leptin may regulate weight gain differentially at 1st versus 2nd trimester of pregnancy: at 2nd trimester, higher leptin levels were associated with greater subsequent weight gain – the opposite of its physiologic regulation in non-pregnancy – and this association was stronger in overweight women. We suspect the existence of a feed-forward signal from leptin in second half of pregnancy, stimulating a positive energy balance and leading to greater weight gain.


  • Open Access

    CSII

    by Jean-Luc Ardilouze, Julie Ménard, Fernand Gobeil, Maude Gagnon-Auger, Ghislaine Houde, Marie-Hélène Pesant, Rémi Rabasa-Lhoret, Jean-Patrice Baillargeon


  • Regulation of blood flow in adipose tissue: involvement of the cholinergic system

    by Richard Sotorník, Jean-Patrice Baillargeon, Maude Gagnon-Auger, Julie Ménard, Pascal Brassard, Jean-Luc Ardilouze

    Acetylcholine (Ach) has vasodilatory actions. However, data are conflicting about the role of Ach in regulating blood flow in subcutaneous adipose tissue (ATBF). This may be related to inaccurate ATBF recording or to the responder/nonresponder (R/NR) phenomenon. We showed previously that healthy individuals are R (ATBF increases postprandially by >50% of baseline BF) or NR (ATBF increases ≤50% postprandially). Our objective was to assess the role of the cholinergic system on ATBF in R and NR subjects. ATBF was manipulated by in situ microinfusion of vasoactive agents (VA) in AT and monitored by the133Xenon washout technique (both recognized methods) at the VA site and at the control site. We tested incrementally increasing doses of Ach (10−5, 10−3, and 10−1mol/l; n = 15) and Ach receptor antagonists (Ra) before and after oral administration of 75-g glucose using atropine (muscarinic Ra; 10−4mol/l, n = 13; 10−5mol/l, n = 22) and mecamylamine (nicotinic Ra; 10−3mol/l, n = 15; 10−4mol/l, n = 10). Compared with baseline [2.41 (1.36–2.83) ml·100 g−1·min−1], Ach increased ATBF dose dependently [3.32 (2.80–5.09), 6.46 (4.36–9.51), and 10.31 (7.98–11.52), P < 0.0001], with no difference between R and NR. Compared with control side, atropine (both concentrations) had no effect on fasting ATBF; only atropine 10−4mol/l decreased post-glucose ATBF [iAUC: 1.25 (0.32–2.91) vs. 1.98 (0.64–2.94); P = 0.04]. This effect was further apparent in R. Mecamylamine had no impact on fasting and postglucose ATBF in R and NR. Our results suggest that the cholinergic system is implicated in ATBF regulation, although it has no role in the blunting of ATBF response in NR.


  • Glycation of Fetal Hemoglobin Reflects Hyperglycemia Exposure In Utero

    by Felix O. Dupont, Marie-France Hivert, Catherine Allard, Julie Ménard, Patrice Perron, Luigi Bouchard, Julie Robitaille, Jean-Charles Pasquier, Christiane Auray-Blais, Jean-Luc Ardilouze

    OBJECTIVE The lifetime risk of metabolic diseases in offspring of women with gestational diabetes mellitus (GDM) depends, at least in part, on the impact of glycemic fetal programming. To quantify this impact, we have developed and validated a unique mass spectrometry method to measure the percentage of glycated hemoglobin in cord blood. RESEARCH DESIGN AND METHODS This case-control study includes 37 GDM women and 30 pregnant women with normal glucose tolerance (NGT). RESULTS Glycation of the α-chain (Glα) was higher in neonates from GDM (2.32 vs. 2.20%, P < 0.01). Glα strongly correlated with maternal A1C measured at delivery in the overall cohort (r = 0.67, P < 0.0001) as well as in each group (GDM: r = 0.66, P < 0.0001; NGT: r = 0.50, P = 0.01). CONCLUSIONS Thus, Glα may reflect hyperglycemic exposure during the last weeks of fetal development. Future studies will confirm Glα is a predictive biomarker of prenatally programmed lifetime metabolic health and disease.


  • Update on adipose tissue blood flow regulation

    by Richard Sotornik, Pascal Brassard, Elizabeth Martin, Philippe Yale, André C. Carpentier, Jean-Luc Ardilouze

    According to Fick's principle, any metabolic or hormonal exchange through a given tissue depends on the product of the blood flow to that tissue and the arteriovenous difference. The proper function of adipose tissue relies on adequate adipose tissue blood flow (ATBF), which determines the influx and efflux of metabolites as well as regulatory endocrine signals. Adequate functioning of adipose tissue in intermediary metabolism requires finely tuned perfusion. Because metabolic and vascular processes are so tightly interconnected, any disruption in one will necessarily impact the other. Although altered ATBF is one consequence of expanding fat tissue, it may also aggravate the negative impacts of obesity on the body's metabolic milieu. This review attempts to summarize the current state of knowledge on adipose tissue vascular bed behavior under physiological conditions and the various factors that contribute to its regulation as well as the possible participation of altered ATBF in the pathophysiology of metabolic syndrome.


  • Open Access

    Gestational Diabetes Mellitus: Simplifying the International Association of Diabetes and Pregnancy Diagnostic Algorithm Using Fasting Plasma Glucose

    by Masoud Mahdavian, Marie-France Hivert, Jean-Patrice Baillargeon, Julie Menard, Annie Ouellet, Jean-Luc Ardilouze


  • Open Access

    Dose-Dependent Delay of the Hypoglycemic Effect of Short-Acting Insulin Analogs in Obese Subjects With Type 2 Diabetes

    by Maude Gagnon-Auger, Patrick du Souich, Jean-Patrice Baillargeon, Elisabeth Martin, Pascal Brassard, Julie Ménard, Jean-Luc Ardilouze

    OBJECTIVE: Injected volume and subcutaneous adipose tissue blood flow (ATBF) affect insulin absorption. Pharmacokinetics of short-acting insulin analogs were established by assessing injection of small doses in lean subjects, healthy or with type 1 diabetes. In obese patients, however, daily dosages are larger and ATBF is decreased. This study assessed the kinetics of a short-acting insulin analog in obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: Euglycemic clamps after subcutaneous lispro injections were performed. Six healthy control subjects received 10 units. Seven obese (BMI 38.3 ± 7.0 kg/m2) subjects with type 2 diabetes received 10, 30, and 50 units. Plasma lispro was measured by specific radioimmunoassay and ATBF by the 133Xe-washout technique. RESULTS: ATBF was 64% lower in subjects with type 2 diabetes than in control subjects. After 10 units injection, time to lispro plasma peak (Tmax) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (Cmax)/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIRmax: 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively). After 30- and 50-unit injections, Tmax (88.6 and 130.0 min, respectively) and time to GIRmax (175 and 245 min) were further delayed and dose related (r2 = 0.51, P = 0.0004 and r2 = 0.76, P < 0.0001, respectively). CONCLUSIONS: Absorption and hypoglycemic action of increasing dosages of lispro are critically delayed in obese subjects with type 2 diabetes.